nct_id: NCT05445778
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2022-07-06'
study_start_date: '2022-12-27'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Mirvetuximab soravtansine plus Bevacizumab'
  - drug_name: 'Drug: Bevacizumab'
long_title: "Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine\
  \ in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy\
  \ for Patients With FR\u03B1-high Recurrent Platinum-sensitive Epithelial Ovarian,\
  \ Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second\
  \ Line Platinum-based Chemotherapy Plus Bevacizumab"
last_updated: '2025-10-03'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: AbbVie
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 520
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- 1. Adult women \>/=18 years old
- 2. Confirmed diagnosis of high-grade serous epithelial ovarian, primary peritoneal,
  or fallopian tube cancer
- "3. Confirmed high FR\u03B1 expression by regulatory-agency approved Ventana FOLR1\
  \ (FOLR1-2.1)"
- 4. Relapsed disease after frontline (first-line) platinum-based chemotherapy and
  must be plantinum-sensitive
- 5. Willing and able to sign the informed consent form (ICF) and adhere to protocol
  requirements
- 6. Negative pregnancy test and willing to use highly effective contraceptive method(s)
  while on study medication and for at least 7 months after the last dose of MIRV
  and 6 months after the last dose of bevacizumab
- 'Exclude - Exclusion Criteria:'
- Exclude - 1. Endometrioid, clear cell, mucinous, or sarconmatous histology; mixed
  tumors containing any of the above or low grade/borderline ovarian tumor
- Exclude - 2. More than one line of prior chemotherapy before current/planned triplet
  therapy
- Exclude - 3. PD (progressive disease) while on or following platinum-based therapy
- Exclude - 4. Prior or whole-pelvis or wide-field radiotherapy
- Exclude - 5. \> Grade 1 peripheral neuropathy
- Exclude - 6. History of or concurrent ocular disorders
- Exclude - 7. Grade 4 thromboembolic events
- Exclude - 8. Not appropriate for bevacizumab treatment
- Exclude - 9. Requiring use of folate-containing supplements
- Exclude - 10. Prior hypersensitivity to monoclonal antibodies
- Exclude - 11. Pregnant or breatfeeding women
- "Exclude - 12. Received prior MIRV or other FR\u03B1-targeting agents"
- Exclude - 13. Untreated or symptomatic central nervous system metastases
- Exclude - 14. History of other malignancy within 3 years prior to signing study
  consent
short_title: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance
  in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: AbbVie
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: "GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate\
  \ the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance\
  \ therapy in participants with platinum-sensitive ovarian, primary peritoneal or\
  \ fallopian tube cancers with high folate receptor-alpha (FR\u03B1) expression."
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Arm 1
      arm_internal_id: 0
      arm_description: Mirvetuximab Soravtansine (MIRV) plus Bevacizumab
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Mirvetuximab soravtansine plus Bevacizumab'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Arm 2
      arm_internal_id: 1
      arm_description: Bevacizumab monotherapy
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Bevacizumab'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: Peritoneal Mesothelioma
        - clinical:
            oncotree_primary_diagnosis: Ovarian Epithelial Tumor
        - clinical:
            oncotree_primary_diagnosis: Ovarian Cancer, Other
        - clinical:
            oncotree_primary_diagnosis: Peritoneal Serous Carcinoma
      - clinical:
          age_numerical: '>=18'
          gender: Female
          disease_status:
          - Recurrent
          - Metastatic
